A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate
the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult
subjects. The purpose of this study is to assess Elafin that is being developed for treatment
of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and
is a major factor in the development of PAH. Elafin will be administered subcutaneously daily
for 7 days in normal healthy subjects followed over a 28 day time period.